| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
Angiotensin II (Ang II), Matrix Metalloproteinase-2 (MMP-2), Matrix Metalloproteinase-9 (MMP-9), Tissue Inhibitor of Metalloproteinase-1 (TIMP-1), Endothelin-1 (ET-1), Transforming Growth Factor-β1 (TGF-β1). [1]
|
|---|---|
| ln Vivo |
Ventricular remodeling benefits with angoroside C. The mechanism could involve lowering Ang II levels and decreasing ET-1 and TGF-β1 mRNA expression [1].
In a pressure-overload rat model induced by abdominal aortic constriction (AAC), oral administration of Angoroside C (7.5, 15, 30 mg/kg/day for 4 weeks) significantly reduced systolic and diastolic blood pressure at the 30 mg/kg dose compared to the model control group. It also markedly decreased left ventricular weight index (LVWI) and heart weight index (HWI), indicating attenuation of cardiac hypertrophy. Histological analysis showed that Angoroside C treatment reduced cardiomyocyte cross-sectional area and decreased collagen deposition (perivascular collagen area and collagen volume fraction), including collagen types I and III. Furthermore, it lowered the elevated levels of cardiac angiotensin II (Ang II) and hydroxyproline (Hyp). Serum analysis revealed that Angoroside C (30 mg/kg) decreased the elevated concentrations of MMP-2 and MMP-9 while increasing the level of TIMP-1, thereby reducing the MMP-2/TIMP-1 and MMP-9/TIMP-1 ratios. Real-time RT-PCR analysis of left ventricular tissue demonstrated that Angoroside C down-regulated the increased mRNA expressions of ET-1 and TGF-β1.[1] |
| Animal Protocol |
A ventricular remodeling model was established in male SD rats by constricting the abdominal aorta between the renal arteries to a diameter of 0.6 mm (AAC surgery). Sham-operated rats underwent the same procedure without constriction. Post-surgery, AAC rats were randomly divided into groups: model control, three Angoroside C treatment groups (7.5, 15, 30 mg/kg), and a positive control captopril group (40 mg/kg). Angoroside C and captopril were suspended in distilled water. Drugs or vehicle (distilled water) were administered orally by gavage once daily, starting one day after surgery and continuing for 4 weeks. After 4 weeks, blood pressure was measured via a catheter inserted into the right carotid artery under anesthesia. Blood was collected for serum preparation. Hearts were excised to measure weight and calculate indices (LVWI, HWI). Left ventricular tissue was used for biochemical analysis (Ang II, Hyp), histological staining (H&E for cardiomyocyte area, Sirius Red for collagen), and RNA extraction for real-time RT-PCR.[1]
|
| References | |
| Additional Infomation |
It has been reported that Angoraglycoside C is found in Scrophularia nodosa, Buddleja davidii, and other organisms with relevant data. Angoraglycoside C is a phenylpropanoid glycoside isolated from Scrophularia ningpoensis Hemsl. This study investigated its effects on pressure-induced ventricular remodeling. The results showed that the beneficial effects of Angoraglycoside C on cardiac hypertrophy and fibrosis may be related to its ability to reduce angiotensin II (Ang II) levels, weaken endothelin-1 (ET-1) and transforming growth factor-β1 (TGF-β1) mRNA expression, thereby regulating extracellular matrix homeostasis (MMPs/TIMPs) and reducing collagen deposition. [1]
|
| Molecular Formula |
C36H48O19
|
|---|---|
| Molecular Weight |
784.7549
|
| Exact Mass |
784.278
|
| CAS # |
115909-22-3
|
| PubChem CID |
23757181
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
985.7±65.0 °C at 760 mmHg
|
| Flash Point |
301.7±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.652
|
| LogP |
2.66
|
| Hydrogen Bond Donor Count |
9
|
| Hydrogen Bond Acceptor Count |
19
|
| Rotatable Bond Count |
15
|
| Heavy Atom Count |
55
|
| Complexity |
1210
|
| Defined Atom Stereocenter Count |
14
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)OC)CO[C@H]4[C@@H]([C@H]([C@H](CO4)O)O)O)OCCC5=CC(=C(C=C5)OC)O)O)O)O)O
|
| InChi Key |
KLQXMRBGMLHBBQ-DQTDZZOCSA-N
|
| InChi Code |
InChI=1S/C36H48O19/c1-16-26(41)28(43)30(45)36(52-16)55-33-31(46)35(49-11-10-18-5-8-22(47-2)20(38)12-18)53-24(15-51-34-29(44)27(42)21(39)14-50-34)32(33)54-25(40)9-6-17-4-7-19(37)23(13-17)48-3/h4-9,12-13,16,21,24,26-39,41-46H,10-11,14-15H2,1-3H3/b9-6+/t16-,21-,24+,26-,27-,28+,29+,30+,31+,32+,33+,34-,35+,36-/m0/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2-[[(2S,3R,4S,5S)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-3-yl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~125 mg/mL (~159.29 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (2.65 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (2.65 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (2.65 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.2743 mL | 6.3715 mL | 12.7429 mL | |
| 5 mM | 0.2549 mL | 1.2743 mL | 2.5486 mL | |
| 10 mM | 0.1274 mL | 0.6371 mL | 1.2743 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
